Intellia Therapeutics to present data from the Phase 2 study of NTLA-2002 for the treatment of hereditary angioedema (HAE) at the 2024 ACAAI Annual...
Vous n'êtes pas connecté
- English
- Français
- عربي
- Español
- Deutsch
- Português
- русский язык
- Català
- Italiano
- Nederlands, Vlaams
- Norsk
- فارسی
- বাংলা
- اردو
- Azərbaycan dili
- Bahasa Indonesia
- Հայերեն
- Ελληνικά
- Bosanski jezik
- українська мова
- Íslenska
- Türkmen, Түркмен
- Türkçe
- Shqip
- Eesti keel
- magyar
- Қазақ тілі
- Kalaallisut ; kalaallit oqaasii
- Lietuvių kalba
- Latviešu valoda
- македонски јазик
- Монгол
- Bahasa Melayu ; بهاس ملايو
- ဗမာစာ
- Slovenščina
- тоҷикӣ ; toğikī ; تاجیکی
- ไทย
- O'zbek ; Ўзбек ; أۇزبېك
- Tiếng Việt
- ភាសាខ្មែរ
- རྫོང་ཁ
- Soomaaliga ; af Soomaali
Rubriques :
Maroc - HAEI.ORG - A La Une - 12/Aug 08:18
Astria chooses Ypsomed’s YpsoMate as injection device for STAR-0215 for treatment of HAE
Astria Therapeutics chooses Ypsomed’s YpsoMate as the injection device for STAR-0215 for the treatment of hereditary angioedema Astra Therapeutics announced that it has chosen Ypsomed as its partner for the development of an autoinjector for STAR-0215. John Ruesch, Senior Vice President, Pharmaceutical Sciences and Technical Operations at Astria, said: “With STAR-0215's profile, our goal [...]
Articles similaires
KalVista announces FDA acceptance of NDA for sebetralstat for oral on-demand treatment of HAE
haei.org - 03/Sep 17:29
KalVista announces FDA acceptance of New Drug Application for sebetralstat for oral on-demand treatment of hereditary angioedema KalVista...
Pharvaris presents deucrictibant long-term extension data for both the prophylactic and on-demand treatment of HAE at the Bradykinin Symposium 2024
haei.org - 05/Sep 18:45
Pharvaris presents deucrictibant long-term extension data for both the prophylactic and on-demand treatment of HAE at the Bradykinin Symposium 2024...
KalVista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary Angioedema
drugs.com - 03/Sep 20:09
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--Sep. 3, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the U.S....
Pharvaris provides business update and expands development program for deucrictibant
haei.org - 05/Sep 18:44
Pharvaris provides business update and expands development program for deucrictibant Pharvaris today announced: The planned initiation of CHAPTER-3,...
BioCryst presents new Orladeyo (berotralstat) data at 7th Bradykinin Symposium
haei.org - 06/Sep 18:48
BioCryst presents new Orladeyo (berotralstat) data at 7th Bradykinin Symposium BioCryst Pharmaceuticals today announced the presentation of six...
KIT FOR THE PREPARATION OF TECHNETIUM TC 99M MEBROFENIN injection, powder, lyophilized, for solution [Sun Pharmaceutical Industries, Inc.]
nlm.nih.gov - 09/Sep 04:00
Updated Date: Mon, 09 Sep 2024 00:00:00 EDT
KIT FOR THE PREPARATION OF TECHNETIUM TC 99M MEBROFENIN injection, powder, lyophilized, for solution [Sun Pharmaceutical Industries, Inc.]
nlm.nih.gov - 09/Sep 04:00
Updated Date: Mon, 09 Sep 2024 00:00:00 EDT
KIT FOR THE PREPARATION OF TECHNETIUM TC 99M MEDRONATE (tc 99m medronate) injection, powder, lyophilized, for solution [Sun Pharmaceutical Industries, Inc.]
nlm.nih.gov - 12/Sep 04:00
Updated Date: Thu, 12 Sep 2024 00:00:00 EDT
KIT FOR THE PREPARATION OF TECHNETIUM TC 99M MEDRONATE (tc 99m medronate) injection, powder, lyophilized, for solution [Sun Pharmaceutical Industries, Inc.]
nlm.nih.gov - 12/Sep 04:00
Updated Date: Thu, 12 Sep 2024 00:00:00 EDT
Les derniers communiqués
-
Aucun élément